Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RODEO: Pre-operative Dostarlimab in Endometrial Cancer
NCT07115927Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Sep 2025
- Primary completion
- Apr 2030
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in endometrial cancer (EC), sponsored by University College London. Primary endpoint: Pathological response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07115927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115927.